U.S. Stock Market Midday Update
MapLight Therapeutics rose 11.58%. Based on recent news,
<ol>
<li>On December 4th, MapLight Therapeutics released the latest clinical trial results, showing significant progress in its new drug for treating a rare disease. This news boosted market confidence, driving the stock price up by 11.58%. The biopharmaceutical industry has performed strongly recently, with investors focusing on new drug development progress.</li>
</ol>
Top Stocks by Industry Trading Volume
Amgen fell 1.37%. Based on recent news,
<ol>
<li>
On December 4th, BMO Capital raised Amgen's target price from $335 to $372, maintaining an &#34;Outperform&#34; rating. This reflects analysts' continued confidence in the biotechnology group, causing stock price fluctuations.
</li>
<li>
On December 4th, Amgen reported strong third-quarter results, primarily driven by sales growth of Repatha and strong contributions from Prolia and rare disease drugs, leading to an upward revision of full-year 2025 guidance. Investors are also optimistic about updates on the obesity candidate drug MariTide and the lung cancer therapy Imdelltra.
</li>
<li>
On December 3rd, Goldman Sachs reiterated its Buy rating on Amgen and set a target price of $400 ahead of key updates on the Phase II trial of the obesity drug MariTide. The drug showed significant weight loss effects in preliminary results and improved cardiac metabolic parameters, enhancing market confidence. The biotechnology industry has performed strongly recently, with clear policy support.
</li>
</ol>
PerkinElmer fell 0.11%. Based on recent key news:
<ol>
<li>
On December 2nd, China's early cancer screening market for the digestive tract is rapidly growing, with policy support driving market expansion. With the release of the &#34;Expert Consensus on Colorectal Cancer Screening for Community Residents in China,&#34; the penetration of molecular diagnostic technology in early colorectal cancer screening has increased, revealing market scale effects. Source: Zhitong Finance
</li>
<li>
On December 2nd, the project in Hanjiang District adopted multi-gene methylation technology for blood tests for colorectal cancer, improving screening compliance. This project established a &#34;molecular initial screening + endoscopic confirmation&#34; dual-stage pathway, effectively alleviating pressure on medical resources and providing a replicable prevention and control model. Source: Zhitong Finance
</li>
<li>
On December 2nd, technological innovation is driving market expansion, with molecular diagnostic products changing the traditional screening landscape. Industry analysis indicates that companies with core technology and commercialization capabilities will gain a sustained competitive advantage. Source: Zhitong Finance The early cancer screening market is entering a golden development period.
</li>
</ol>
Forte Pharmaceuticals fell 1.42%. Based on recent key news:
<ol>
<li>
On December 4th, Forte Pharmaceuticals opened strong, with significant movements in main funds, multiple rounds of probing upward during the day, and an overall acceleration in sector rhythm. Positive FDA news stimulated speculation in innovative drugs, with analysts raising ratings, driving stock price fluctuations. Source: Zhitong Finance
</li>
<li>
Recently, there have been no major negative factors at high levels; instead, there are catalysts from analysts raising ratings, with several mainline innovative drugs showing significant buying effects. FOMO sentiment has surged to new highs amid sector rotation, with technical indicators MACD/KDJ turning upward consecutively, and main funds' protective actions directly lifting the bottom
Source: Zhitong Finance
</li>
<li>
Community views remain strong on the core track, but the risks brought by high-level speculation are also magnified. Short-term chasing highs must be closely monitored, as the market may experience a breather under sector rotation, potentially reverting to lower levels at any time. Source: Zhitong Finance The pharmaceutical sector has recently shown active performance, with significant capital inflow.
</li>
</ol>
Stocks ranked at the forefront of industry market capitalization
AbbVie fell 0.82%. Based on recent news,
<ol>
<li>
On December 2, AbbVie presented the latest data on various new therapies for blood cancers at the ASH 2025 conference. This data showcased the progress of T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates in various blood cancers, demonstrating significant efficacy signals but also highlighting safety issues such as neutropenia and infections. This new data may spark market expectations for the company's future growth, but it also brings certain safety concerns.
</li>
<li>
On December 2, AbbVie announced the Phase III data of the ECLIPSE study at the 19th European Headache Congress, showing the superiority of Atogepant in the treatment of acute migraine. This data supports the efficacy of Atogepant in this indication and may enhance market confidence in the drug.
</li>
<li>
On December 5, AbbVie's immunology business continued to show strong growth after losing patent protection for Humira, primarily driven by Skyrizi and Rinvoq. The combined sales of these two drugs grew by 53% year-on-year, reaching $18.5 billion, and are expected to exceed $31 billion by 2027. This growth expectation may boost investor confidence. Strong growth is observed in the fields of immunology and neuroscience, with intense competition
</li>
</ol>

MPLT

MapLight Therapeutics rose 11.58%; Amgen fell 1.37%, with a transaction volume of USD 732 million; Precision BioSciences fell 0.11%, with a transaction volume of USD 702 million; Fortis Pharmaceuticals fell 1.42%, with a transaction volume of USD 425 million; AbbVie fell 0.82%, with a market capitalization of USD 403.7 billion

U.S. Stock Market Midday Update: MapLight Therapeutics makes significant progress in new drug trials, stock price surges 11.58%